Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
Diego Sánchez‐Martínez, Nerea Allende-Vega, Stefania Orecchioni, et al.
Theranostics (2018) Vol. 8, Iss. 14, pp. 3856-3869
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano del Valle, Alberto Anel, Javier Naval, et al.
Frontiers in Cell and Developmental Biology (2019) Vol. 7
Open Access | Times Cited: 176
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Babak Nami, Hamid Maadi, Zhixiang Wang
Cancers (2018) Vol. 10, Iss. 10, pp. 342-342
Open Access | Times Cited: 149
Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy
Xue Liu, Chao Liu, Zizheng Zheng, et al.
Advanced Materials (2019) Vol. 31, Iss. 17
Closed Access | Times Cited: 81
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
Loïs Coënon, Martín Villalba
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
Hasan Baysal, Ines De Pauw, Hannah Zaryouh, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 47
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Xiao Wang, Xuejiao Yang, Xiang Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 35
Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review
Alvin Man Lung Chan, Jin Min Cheah, Yogeswaran Lokanathan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4026-4026
Open Access | Times Cited: 17
Cell membrane-encapsulated magnetic nanoparticles for enhancing natural killer cell-mediated cancer immunotherapy
Dan Wu, Xin Shou, Yalan Zhang, et al.
Nanomedicine Nanotechnology Biology and Medicine (2020) Vol. 32, pp. 102333-102333
Closed Access | Times Cited: 45
The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
Sana Belkahla, Joaquín Marco-Brualla, Alexis Fayd’herbe de Maudave, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
Nerea Allende-Vega, Joaquín Marco-Brualla, Paolo Falvo, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
Maria Karvouni, Marcos Vidal-Manrique, Andreas Lundqvist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma
Xiyue Xu, Yidan Zhang, Yaxiao Lu, et al.
Cancer Research (2024) Vol. 84, Iss. 13, pp. 2123-2140
Closed Access | Times Cited: 5
ICAM‐1 Is Overexpressed by Cancers and Negatively Impacts Antibody‐Based Therapies Including Antibody–Drug Conjugates
J. Bradford Kline, Luigi Grasso, Nicholas C. Nicolaides
European Journal of Immunology (2025) Vol. 55, Iss. 3
Closed Access
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
Chantal Reina-Ortiz, Michael G. Constantinides, Alexis Fayd’herbe de Maudave, et al.
OncoImmunology (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 34
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3
Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death
Yongbin Ye, Ning Liu, Yunxin Zeng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Expansion and activation of NK cells supported by accessory cells. Phenotypic and functional characterization
Cecilia Pesini, Pilar M. Lanuza, Julián Pardo, et al.
Methods in cell biology (2025)
Closed Access
Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance
Tania Calvo, Chantal Reina-Ortiz, David Giraldos, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 31
A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients
Jianfeng Ding, Xiaobo He, Xiao Cheng, et al.
World Journal of Surgical Oncology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 23
Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer
Catherine Alexia, Maïlys Cren, Pascale Louis‐Plence, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 27
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
Max Yano, John C. Byrd, Natarajan Muthusamy
Cancers (2022) Vol. 14, Iss. 23, pp. 5787-5787
Open Access | Times Cited: 14
Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
Martín Villalba, Catherine Alexia, Anais Bellin-Robert, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 23
NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations
Carlos E. Sanchez, Ehsan Dowlati, Ashley Geiger, et al.
Transplantation and Cellular Therapy (2020) Vol. 27, Iss. 1, pp. 21-35
Open Access | Times Cited: 21
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications
Paolo Sportoletti, Filomena De Falco, Beatrice Del Papa, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6665-6665
Open Access | Times Cited: 19
Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 392-392
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top